WO2000003029A3 - Chimaeric adenoviruses - Google Patents

Chimaeric adenoviruses Download PDF

Info

Publication number
WO2000003029A3
WO2000003029A3 PCT/NL1999/000436 NL9900436W WO0003029A3 WO 2000003029 A3 WO2000003029 A3 WO 2000003029A3 NL 9900436 W NL9900436 W NL 9900436W WO 0003029 A3 WO0003029 A3 WO 0003029A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenoviruses
chimaeric
gene therapy
decreased
hybrid
Prior art date
Application number
PCT/NL1999/000436
Other languages
French (fr)
Other versions
WO2000003029A2 (en
Inventor
Menzo Havenga
Ronald Vogels
Abraham Bout
Original Assignee
Introgene Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgene Bv filed Critical Introgene Bv
Priority to CA2303477A priority Critical patent/CA2303477C/en
Priority to JP2000559250A priority patent/JP4472178B2/en
Priority to NZ503018A priority patent/NZ503018A/en
Priority to AU49356/99A priority patent/AU765276B2/en
Publication of WO2000003029A2 publication Critical patent/WO2000003029A2/en
Publication of WO2000003029A3 publication Critical patent/WO2000003029A3/en
Priority to AU2003268608A priority patent/AU2003268608B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention provides methods and vector systems for the generation of chimaeric recombinant adenoviruses. These hybrid adenoviruses contain a genome that is derived from different adenovirus serotypes. In particular, novel hybrid adenoviruses are disclosed with improved properties for gene therapy purposes. These properties include: a decreased sensitivity towards neutralizing antibodies, a modified host range, a change in the titer to which adenovirus can be grown, the ability to escape trapping in the liver upon in vivo systemic delivery, and absence or decreased infection of antigen presenting cells (APC) of the immune system, such as macrophages or dendritic cells. These chimaeric adenoviruses thus represent improved tools for gene therapy and vaccination since they overcome the limitations observed with the currently used serotype subgroup C adenoviruses.
PCT/NL1999/000436 1998-07-08 1999-07-08 Chimaeric adenoviruses WO2000003029A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2303477A CA2303477C (en) 1998-07-08 1999-07-08 Chimaeric adenoviruses
JP2000559250A JP4472178B2 (en) 1998-07-08 1999-07-08 Chimeric adenovirus
NZ503018A NZ503018A (en) 1998-07-08 1999-07-08 Chimaeric adenoviruses with reduced antigenicity
AU49356/99A AU765276B2 (en) 1998-07-08 1999-07-08 Chimaeric adenoviruses
AU2003268608A AU2003268608B2 (en) 1998-07-08 2003-12-11 Chimaeric adenoviruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202297 1998-07-08
EP98202297.2 1998-07-08

Publications (2)

Publication Number Publication Date
WO2000003029A2 WO2000003029A2 (en) 2000-01-20
WO2000003029A3 true WO2000003029A3 (en) 2000-03-16

Family

ID=8233905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1999/000436 WO2000003029A2 (en) 1998-07-08 1999-07-08 Chimaeric adenoviruses

Country Status (10)

Country Link
US (3) US20030017138A1 (en)
EP (1) EP0978566B1 (en)
JP (1) JP4472178B2 (en)
AT (1) ATE325200T1 (en)
AU (1) AU765276B2 (en)
CA (1) CA2303477C (en)
DE (1) DE69931112T2 (en)
ES (1) ES2263250T3 (en)
NZ (1) NZ503018A (en)
WO (1) WO2000003029A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE278794T1 (en) 1995-06-15 2004-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
ATE403006T1 (en) * 1999-03-04 2008-08-15 Crucell Holland Bv USE OF AN ADENOVIRUS VECTOR FOR TRANSDUCING SYNOVIAL CELLS
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (en) * 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19956763A1 (en) * 1999-11-25 2001-06-13 Guenter Cichon Reducing interaction of adenoviral vectors with blood cells, useful for ex vivo gene therapy, by mutating the fiber-encoding gene in vectors or helper constructs, reduces toxicity
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
EP1191105A1 (en) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
US7754201B2 (en) * 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
DE60116513T2 (en) * 2000-08-10 2006-09-21 Crucell Holland B.V. ADENOVIRENVEKTOREN FOR THE TRANSDUCTION OF CHONDROCYTES
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
EP1195440A1 (en) * 2000-10-06 2002-04-10 Introgene B.V. Gene delivery vectors for stem cells
AU2002211087A1 (en) * 2000-10-06 2002-04-15 Crucell Holland B.V. Gene delivery vectors for stem cells
AU2002314705A1 (en) * 2001-01-09 2002-10-28 Beverly L. Davidson Adenovirus serotype 30 (ad30) fiber protein and uses thereof
US6635466B2 (en) 2001-01-09 2003-10-21 University Of Iowa Research Foundation Adenovirus serotype 30 (Ad30)
IL152423A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel vector constructs
JP2002325573A (en) * 2001-04-27 2002-11-12 Japan Science & Technology Corp Vector
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
AU2002322285A1 (en) 2001-06-22 2003-01-08 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
EP2301582B1 (en) 2001-11-21 2017-07-12 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1 (en) * 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2007201747B2 (en) * 2001-11-21 2010-06-03 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1516055A4 (en) * 2002-01-24 2007-08-08 Scripps Research Inst Fiber shaft modifications for efficient targeting
PT1497438E (en) 2002-04-25 2010-02-04 Crucell Holland Bv Means and methods for the production of adenovirus vectors
DK1497440T3 (en) 2002-04-25 2008-12-01 Crucell Holland Bv Stable adenoviral vectors and methods of propagation thereof
WO2004027073A1 (en) * 2002-09-20 2004-04-01 Crucell Holland B.V. Modified adenoviral vectors for use in vaccines and gene therapy
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
WO2004099422A2 (en) 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
CA2527954A1 (en) * 2003-06-11 2004-12-23 The Scripps Research Institute Modified fiber proteins for efficient receptor binding
US7491508B2 (en) 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
DE602005015332D1 (en) 2004-02-23 2009-08-20 Crucell Holland Bv Method for cleaning viruses
CA2836987C (en) * 2004-05-26 2016-07-05 Psioxus Therapeutics Limited Chimeric adenoviruses for use in cancer treatment
KR101253363B1 (en) * 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 Improved adenoviral vectors and uses thereof
WO2006108707A1 (en) 2005-04-11 2006-10-19 Crucell Holland B.V. Virus purification using ultrafiltration
CA2627638A1 (en) * 2005-10-28 2007-05-03 Michael James Mathis Conditionally replicating viruses and methods for cancer virotherapy
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
EA028875B1 (en) 2009-10-15 2018-01-31 Янссен Вэксинс Энд Превеншн Б.В. Method for purifying adenovirus particles from a cell suspension
KR101749779B1 (en) 2009-10-15 2017-06-21 크루셀 홀란드 비.브이. Method for the purification of adenovirus particles
JP5981916B2 (en) * 2010-08-16 2016-09-07 ソーク インスティテュート フォー バイオロジカル スタディーズ Method for constructing adenovirus
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
EP2855669B1 (en) * 2012-05-29 2018-10-10 GenVec, Inc. Modified serotype 28 adenoviral vectors
JP6576326B2 (en) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ Oncolytic adenovirus composition
EP3046536B1 (en) 2013-09-19 2018-11-28 Janssen Vaccines & Prevention B.V. Improved adenovirus formulations
PL3021859T3 (en) 2013-10-25 2018-06-29 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
PL3288573T3 (en) 2015-04-30 2020-05-18 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein
US20170067028A1 (en) * 2015-05-15 2017-03-09 Douglas J. Ballon Radiolabeling of adeno associated virus
EA036412B1 (en) 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Method for protecting an adenovirus from plastic-induced degradation and use of 2-hydroxypropyl--cyclodextrin for protecting the adenovirus
WO2017103291A1 (en) 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US11896634B2 (en) 2017-04-21 2024-02-13 Baylor College Of Medicine Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules
WO2018218240A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023545731A (en) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド Therapeutic adeno-associated virus delivery of fukutin-related protein (FKRP) to treat dystroglycanopathy disorders including limb girdle type 2I (LGMD2I)
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013597A2 (en) * 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
WO1996026281A1 (en) * 1995-02-21 1996-08-29 Genvec, Inc. Chimeric adenoviral fiber protein and methods of using same
WO1997020051A2 (en) * 1995-11-28 1997-06-05 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1998022609A1 (en) * 1996-11-20 1998-05-28 Genzyme Corporation Chimeric adenoviral vectors
WO1998040509A1 (en) * 1997-03-13 1998-09-17 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) * 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
FR2602790B1 (en) 1986-08-13 1990-06-01 Transgene Sa EXPRESSION OF A SPECIFIC TUMOR ANTIGEN BY A RECOMBINANT VECTOR VIRUS AND USE THEREOF FOR THE PREVENTIVE OR CURATIVE TREATMENT OF THE CORRESPONDING TUMOR
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5585254A (en) * 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5204445A (en) * 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE69032841T2 (en) * 1989-01-23 1999-05-12 Chiron Corp RECOMBINANT CELLS FOR INFECTIVE THERAPIES AND HYPERPROLIEFERATIVE DISORDERS AND THEIR PRODUCTION
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
DE69033181T2 (en) 1989-10-20 1999-10-21 Dartmouth College IGA RECEPTOR-SPECIFIC MONOCLONAL ANTIBODIES
CA2069960C (en) 1989-10-20 2004-03-02 Michael W. Fanger Bispecific heteroantibodies with dual effector functions
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
JP3534749B2 (en) 1991-08-20 2004-06-07 アメリカ合衆国 Adenovirus-mediated gene transfer into the gastrointestinal tract
FR2681786A1 (en) 1991-09-27 1993-04-02 Centre Nat Rech Scient RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS.
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
JPH073958B2 (en) * 1992-01-31 1995-01-18 インターナショナル・ビジネス・マシーンズ・コーポレイション Termination circuit
AU692423B2 (en) 1992-09-25 1998-06-11 Institut National De La Sante Et De La Recherche Medicale Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0668913B1 (en) 1992-11-18 2002-01-30 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
AU6133394A (en) 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
DE4311651A1 (en) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
ES2180579T3 (en) 1993-05-10 2003-02-16 Univ Michigan TRANSFER OF GENES IN PANCREATIC EPITHELIAL CELLS.
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
EP0716711A1 (en) 1993-09-03 1996-06-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vector for gene therapy of the liver
US5552311A (en) * 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
FR2712812B1 (en) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition for the production of therapeutic products in vivo.
IT1271461B (en) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE.
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6312699B1 (en) 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE69520496T2 (en) 1994-05-13 2001-07-12 Chiron Corp METHOD AND COMPOSITIONS AS VEHICLES FOR TARGETED INTRODUCTION OF GENES
US5560905A (en) * 1994-05-13 1996-10-01 The Proctor & Gamble Company Oral compositions
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US5570975A (en) 1994-06-27 1996-11-05 Reinert, Sr.; Gary L. Metal foundation push-it and installation apparatus and method
FR2721943B1 (en) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa ADENOVIRUS COMPRISING A GENE ENCODING A SUPEROXIDE DISMUTASE
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
JPH10508743A (en) 1994-09-09 1998-09-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Interleukin-1 type 3 receptor
FR2724846B1 (en) 1994-09-27 1996-12-20 Rhone Poulenc Rorer Sa METHOD OF TREATING CANCER BY REGULATING THE ACTIVITY OF RAS PROTEINS
FR2725726B1 (en) * 1994-10-17 1997-01-03 Centre Nat Rech Scient VIRAL VECTORS AND USE IN GENE THERAPY
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996014837A1 (en) 1994-11-09 1996-05-23 Genetic Therapy, Inc. Gene therapy for hypercholesterolemia
ATE195555T1 (en) 1994-11-29 2000-09-15 Takara Shuzo Co METHOD FOR PRODUCING TRANSFORMED CELLS
FR2727867B1 (en) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS
AUPN107195A0 (en) 1995-02-10 1995-03-09 Withers, Graham Rex Metal matrix forming method and apparatus
JPH11511651A (en) 1995-05-10 1999-10-12 イントロヘーネ ベスローテン フェンノートシャップ Improved retroviral vectors particularly suitable for gene therapy
ATE278794T1 (en) * 1995-06-15 2004-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
JP2001520511A (en) 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション Targeting adenovirus vector
WO1997038723A1 (en) 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
ATE296117T1 (en) * 1997-03-07 2005-06-15 Wistar Inst USE OF ADENOVIRAL VECTORS EXPRESSING PDGF OR VEGF TO HEAL TISSUE DEFECTS AND TO INDUCE HYPERVASCULISM IN MAMMAL TISSUES
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
IL132673A0 (en) * 1997-05-08 2001-03-19 Genetic Therapy Inc Gene transfer with adenoviruses having modified fiber proteins
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6287857B1 (en) * 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
WO1999047180A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1112372A1 (en) * 1998-09-11 2001-07-04 Genvec, Inc. Alternatively targeted adenovirus
EP1020529B1 (en) 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6869936B1 (en) * 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
ATE364707T1 (en) 1999-05-17 2007-07-15 Crucell Holland Bv RECOMBINANT HUMAN ADENOVIRUS SEROTYPE 35
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
EP1157999A1 (en) 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
DE60116513T2 (en) * 2000-08-10 2006-09-21 Crucell Holland B.V. ADENOVIRENVEKTOREN FOR THE TRANSDUCTION OF CHONDROCYTES
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013597A2 (en) * 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
WO1996026281A1 (en) * 1995-02-21 1996-08-29 Genvec, Inc. Chimeric adenoviral fiber protein and methods of using same
WO1997020051A2 (en) * 1995-11-28 1997-06-05 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1998022609A1 (en) * 1996-11-20 1998-05-28 Genzyme Corporation Chimeric adenoviral vectors
WO1998040509A1 (en) * 1997-03-13 1998-09-17 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GALL J. ET AL.: "ADENOVIRUS TYPE 5 AND 7 CAPSID CHIMERA: FIBER REPLACEMENT ALTERS RECEPTOR TROPISM WITHOUT AFFECTING PRIMARY IMMUNE NEUTRALIZATION EPITOPES", JOURNAL OF VIROLOGY, vol. 70, no. 4, April 1996 (1996-04-01), pages 2116 - 2123, XP002050655 *
MASTRANGELI A. ET AL.: ""SERO-SWITCH" ADENOVIRUS-MEDIATED IN VIVO GENE TRANSFER: CIRCUMVENTION OF ANTI-ADENOVIRUS HUMORAL IMMUNE DEFENSES AGAINST REPEAT ADENOVIRUS VECTOR ADMINISTRATION BY CHANGING THE ADENOVIRUS SEROTYPE", HUMAN GENE THERAPY, vol. 7, no. 1, 1 January 1996 (1996-01-01), pages 79 - 87, XP000653452 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Also Published As

Publication number Publication date
AU4935699A (en) 2000-02-01
US7749493B2 (en) 2010-07-06
CA2303477A1 (en) 2000-01-20
ES2263250T3 (en) 2006-12-01
AU765276B2 (en) 2003-09-11
US20030017138A1 (en) 2003-01-23
JP2002520026A (en) 2002-07-09
US20030073072A1 (en) 2003-04-17
US20060014276A1 (en) 2006-01-19
CA2303477C (en) 2010-04-06
DE69931112D1 (en) 2006-06-08
WO2000003029A2 (en) 2000-01-20
EP0978566A3 (en) 2000-04-19
ATE325200T1 (en) 2006-06-15
NZ503018A (en) 2003-06-30
EP0978566A2 (en) 2000-02-09
DE69931112T2 (en) 2006-12-07
EP0978566B1 (en) 2006-05-03
JP4472178B2 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
WO2000003029A3 (en) Chimaeric adenoviruses
Croyle et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver
Rickinson et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
HUP0101207A2 (en) Live recombined vaccines with adjuvant
Cui et al. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350
Rountree et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy
AU3431497A (en) DNA immunization against Chlaymdia infection
CA2275033A1 (en) Biodegradable targetable microparticle delivery system
MXPA01008966A (en) Nucleic acid respiratory syncytial virus vaccines.
CA2385655A1 (en) Dna immunization against chlamydia infection
Rüedi et al. Antiviral T cell competence and restriction specificity of mixed allogeneic (P1+ P2→ P1) irradiation chimeras
EP1335023A3 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
WO1999058658A3 (en) Expression vectors for stimulating an immune response and methods of using the same
Diniz et al. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D
Welten et al. Fuel and brake of memory T cell inflation
KR20220097440A (en) Viruses with modified capsid proteins
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
Li et al. Enhancement of immunogenic response and protection in model rats by CSTM nanoparticles anticaries DNA vaccine
WO2001021201A3 (en) Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
Bos et al. Cationic polymers that enhance the performance of HbsAg DNA in vivo
US20230321209A1 (en) Modified mycobacterium bovis vaccines
US5686075A (en) Synthetic peptide vaccines for dental caries
ES2748468T3 (en) Recombinant swinepox virus and vaccines
DK0843731T3 (en) Gene therapy adenovirus vectors
Choi et al. Bolstering components of the immune response compromised by prior exposure to adenovirus: guided formulation development for a nasal Ebola vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX NZ

WWE Wipo information: entry into national phase

Ref document number: 503018

Country of ref document: NZ

Ref document number: 49356/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2303477

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2303477

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP MX NZ

WWG Wipo information: grant in national office

Ref document number: 49356/99

Country of ref document: AU